Sorafenib ameliorates renal fibrosis through inhibition of TGF-β-induced epithelial-mesenchymal transition

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Jia, Lining ^a   Ma, Xiaotao ^a   Gui, Baosong ^a   Ge, Heng ^a   Wang, Li ^a   Ou, Yan ^a   Tian, Lifang ^a   Chen, Zhao ^a   Duan, Zhaoyang ^a   Han, Jin ^a   Fu, Rongguo ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; EOSIN; HEMATOXYLIN; SMAD3 PROTEIN; SORAFENIB; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; ACTIN; CADHERIN; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; SMOOTH MUSCLE ACTIN, RAT; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; KIDNEY BLOOD FLOW; KIDNEY FIBROSIS; KIDNEY SIZE; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RAT; SHAM PROCEDURE; SIGNAL TRANSDUCTION; TUBULAR DYSFUNCTION; URETER OBSTRUCTION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GENETICS; KIDNEY DISEASES; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

RATTUS;

ACTINS; ANIMALS; APOPTOSIS; CADHERINS; CELL LINE; DISEASE MODELS, ANIMAL; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROSIS; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASES; MALE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RATS; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; URETERAL OBSTRUCTION;

EID: 84922970268     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117757     Document Type: Article

References (22)

1. Zeisberg M, Neilson EG (2010) Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 21 (11):1819-1834. doi: 10.1681/ASN.2010080793 PMID: 20864689
2. Bechtel W, McGoohan S, Zeisberg EM, Muller GA, Kalbacher H, et al. (2010) Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med 16: 544-550. doi: 10.1038/nm.2135 PMID: 20418885
3. Piera-Velazquez S, Jimenez SA (2012) Molecular mechanisms of endothelial to mesenchymal cell transition (EndoMT) in experimentally induced fibrotic diseases. Fibrogenesis & tissue repair 5 (1):1-5. doi: 10.1038/nprot.2015.017 PMID: 25612230
4. Bae E, Kim SJ, Hong S, Liu F, Ooshima A (2012) Smad3 linker phosphorylation attenuates Smad3 transcriptional activity and TGF-beta1/Smad3-induced epithelial-mesenchymal transition in renal epithelial cells. Biochemical and biophysical research communications 427(3):593-599. doi: 10.1016/j.bbrc.2012.09.103 PMID: 23022526
5. Meng XM, Huang XR, Chung AC, Qin W, Shao X, et al. (2010) Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis. J Am Soc Nephrol 21(9):1477-1487. doi: 10.1681/ASN.2009121244 PMID: 20595680
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390. doi: 10.1056/NEJMoa0708857 PMID: 18650514
7. Martinelli E, Troiani T, Morgillo F, Rodolico G, Vitagliano D, et al. (2010) Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. Clin Cancer Res 16:4990-5001. doi: 10.1158/1078-0432.CCR-10-0923 PMID: 20810384
8. Peer CJ, Sissung TM, Kim A, Jain L, Woo S, et al. (2012) Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin Cancer Res 18(7):2099-2107. doi: 10.1158/1078-0432.CCR-11-2484 PMID: 22307138
9. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, et al. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5:835-844. PMID: 17016424
10. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, et al. (2009) Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 49(4):1245-56. doi: 10.1002/hep.22758 PMID: 19137587
11. Reiberger T, Angermayr B, Schwabl P, Rohr-Udilova N, Mitterhauser M, et al. (2009) Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. Journal of hepatology 51 (5):865-873. doi: 10.1016/j.jhep.2009.06.024 PMID: 19726100
12. Chen YL, Lv J, Ye XL, Sun MY, Xu Q, et al. (2011) Sorafenib inhibits transforming growth factor beta1-mediated epithelial-mesenchymal transition and apoptosis in mouse hepatocytes. Hepatology 53 (5):1708-1718. doi: 10.1002/hep.24254 PMID: 21360571
13. Zhang J, Chen YL, Ji G, Fang W, Gao Z, et al. (2013) Sorafenib inhibits epithelial-mesenchymal transition through an epigenetic-based mechanism in human lung epithelial cells. PloS one 8(5):e64954. doi: 10.1371/journal.pone.0064954 PMID: 23741434
14. Wang Y, Gao J, Zhang D, Zhang J, Ma J, et al. (2010) New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. Journal of hepatology 53(1):132-144. doi: 10.1016/j.jhep.2010.02.027 PMID: 20447716
15. Sonomura K, Okigaki M, Kimura T, Matsuoka E, Shiotsu Y, et al. (2012) The kinase Pyk2 is involved in renal fibrosis by means of mechanical stretch-induced growth factor expression in renal tubules. Kidney international 81(5):449-457. doi: 10.1038/ki.2011.403 PMID: 22157654
16. Thabut D, Routray C, Lomberk G, Shergill U, Glaser K, et al. (2011) Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology 54(2):573-585. doi: 10.1002/hep.24427 PMID: 21567441
17. D'Amico M, Mejias M, Garcia-Pras E, Abraldes JG, Garcia-Pagan JC, et al. (2012) Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats. Am J Physiol Gastrointest Liver Physiol 302(10):1191-1198.
18. Yuanmeng J, Krishna R, Peter Y, et al. (2012) Systems approach identifies HIPK2 as a critical regulator of kidney fibrosis Nat Med 18(4): 580-588. doi: 10.1038/nm.2685 PMID: 22406746
19. Morinaga J, Kakizoe Y, Miyoshi T, Onoue T, Ueda M, et al. (2013) The antifibrotic effect of a serine protease inhibitor in the kidney. American journal of physiology 305(2):F173-181. doi: 10.1152/ajprenal.00586.2012 PMID: 23698112
20. Grimminger F, Schermuly RT, Ghofrani HA (2010) Targeting non-malignant disorders with tyrosine kinase inhibitors., Nature reviews 9(12):956-970. doi: 10.1038/nrd3297 PMID: 21119733
21. Rosenbloom J, Mendoza FA, Jimenez SA (2012) Strategies for anti-fibrotic therapies. Biochimica et biophysica acta 1832(7):1088-1103. doi: 10.1016/j.bbadis.2012.12.007 PMID: 23266403
22. Boffa JJ, Dussaule JC, Ronco P, Chatziantoniou C (2012) Chronic kidney disease, new therapeutic approaches. La Revue du praticien 62(1):72-75. PMID: 22335071